Blog
RSS FeedPosted by Michael Wonder on 09 Sep 2021
Insurance benefits for Pfizer’s heart drug Vyndamax uncertain
9 September 2021 - Pfizer’s Vyndamax (tafamidis), a treatment for transthyretin amyloid cardiomyopathy, got in the European Society of Cardiology’s ...
Posted by Michael Wonder on 07 Sep 2021
Reimbursement uncertain for Piqray targeting PIK3CA mutation in breast cancer
7 September 2021 - The first and only targeted therapy to treat hormone receptor positive and human epidermal growth factor ...
Posted by Michael Wonder on 03 Sep 2021
Acute myeloid leukaemia drug Xospata nears getting insurance benefits
3 September 2021 - Astellas Korea’s Xospata 40mg (gilteritinib fumarate), a treatment for acute myeloid leukaemia, has taken a step ...
Posted by Michael Wonder on 02 Sep 2021
Pfizer’s acromegaly treatment receives reimbursement
2 September 2021 - Pfizer Korea said Thursday that the Ministry of Health and Welfare would begin to reimburse Somavert, ...
Posted by Michael Wonder on 02 Sep 2021
CAR-T therapy Kymriah fails to get insurance benefits
2 September 2021 - The first CAR-T therapy, Kymriah (ingredient: tisagenlecleucel), failed to pass the review of a panel at ...
Posted by Michael Wonder on 01 Sep 2021
Cancer treatments account for 9.3% of total drug claims in 2020
1 September 2021 - The National Health Insurance Service (NHIS) said that the reimbursement claims for anticancer drugs last year ...
Posted by Michael Wonder on 30 Aug 2021
Roche to withdraw 2 Parkinson’s drugs from Korean market
27 August 2021 - Roche said it would withdraw Parkinson’s syndrome treatment Madopar 125 mg and 250 mg tablets from ...
Posted by Michael Wonder on 26 Aug 2021
Government eases criteria for haemophilia A drug reimbursement
26 August 2021 - The Government said it would ease the immune tolerance induction treatment criteria for haemophilia A drug ...
Posted by Michael Wonder on 25 Aug 2021
Avastin biosimilar may bring insurance benefits for Tecentriq
25 August 2021 - The government has been delaying discussing whether to allow reimbursement for Tecentriq (atezolizumab) due to concerns ...
Posted by Michael Wonder on 18 Aug 2021
Talks to recover reimbursement for dementia treatment aid almost complete
18 August 2021 - The negotiations on retrieving the reimbursement of pharmaceutical pricing for choline alfoscerate drugs to help treat ...
Posted by Michael Wonder on 17 Aug 2021
Will Government further expand reimbursement for rare leukaemia drugs?
17 August 2021 - As the Government has gradually increased reimbursement for combination drugs treating chronic lymphocytic leukaemia, patients’ hopes ...
Posted by Michael Wonder on 10 Aug 2021
Companion diagnostics are growing rapidly worldwide. What about in Korea?
10 August 2021 - The global companion diagnostics market is expanding fast, but Korea has yet to develop related technologies, ...
Posted by Michael Wonder on 02 Aug 2021
Novartis’ psoriatic arthritis drug to get expanded reimbursement
2 August 2021 - Novartis Korea said Monday its interleukin-17a inhibitor Cosentyx (secukinumab) began receiving reimbursement as a first-line biologics ...
Posted by Michael Wonder on 28 Jul 2021
'New regulation limiting generic drugs will change industrial paradigm'
27 July 2021 - The Korea Pharmaceutical and Bio-pharma Manufacturers Association said the revision of the Pharmaceutical Affairs Act to ...
Posted by Michael Wonder on 12 Jul 2021
‘MSD Korea proposed unprecedented offer for Keytruda reimbursement’
12 July 2021 - MSD’s Keytruda (pembrolizumab), immunotherapy for lung cancer, is the company’s flagship item that sold $14.38 billion ...